A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Albuterol (salbutamol) is a widely used asthma medication but is associated with undesirable
side effects such as shakiness and increased heart rate. Targeted delivery of albuterol to
area of lungs where it has most effect would require a lower total dose to produce the same
beneficial effects while reducing the side effects.
It is anticipated that only 1/13th to 1/25th of the standard nebulized dose of albuterol will
be required to attain same bronchodilator response as a standard nebulizer treatment as
determined by lung function measurement and that the reduced dose will significantly reduce
side effects as determined by hand tremor and heart rate.